Cargando…
JWA reverses cisplatin resistance via the CK2—XRCC1 pathway in human gastric cancer cells
Gastric cancer is the third most common malignancy in China, with a median 5-year survival of only 20%. Cisplatin has been used in first-line cancer treatment for several types of cancer including gastric cancer. However, patients are often primary resistant or develop acquired resistance resulting...
Autores principales: | Xu, W, Chen, Q, Wang, Q, Sun, Y, Wang, S, Li, A, Xu, S, Røe, O D, Wang, M, Zhang, R, Yang, L, Zhou, J |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4649833/ https://www.ncbi.nlm.nih.gov/pubmed/25476899 http://dx.doi.org/10.1038/cddis.2014.517 |
Ejemplares similares
-
JWA regulates TRAIL-induced apoptosis via MARCH8-mediated DR4 ubiquitination in cisplatin-resistant gastric cancer cells
por: Wang, Q, et al.
Publicado: (2017) -
TXNL1-XRCC1 pathway regulates cisplatin-induced cell death and contributes to resistance in human gastric cancer
por: Xu, W, et al.
Publicado: (2014) -
JWA down-regulates HER2 expression via c-Cbl and induces lapatinib resistance in human gastric cancer cells
por: Ma, Ling, et al.
Publicado: (2016) -
Synergistic Role between p53 and JWA: Prognostic and Predictive Biomarkers in Gastric Cancer
por: Liu, Xin, et al.
Publicado: (2012) -
JWA regulates XRCC1 and functions as a novel base excision repair protein in oxidative-stress-induced DNA single-strand breaks
por: Wang, Shouyu, et al.
Publicado: (2009)